Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 29;4(2):816–827. doi: 10.1021/jacsau.3c00795

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors. Published by American Chemical Society

Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

DSARTC has demonstrated promising potential in inducing AR and AR-V7 degradation as well as inhibiting prostate cancer cells. Detection of cell viability in CWR22Rv1 (A), C4-2 (B), and LNCaP (C) cell lines following treatment with varying concentrations of DSARTAC drugs. Immunoblotting analysis of AR and AR-V7 protein levels in CWR22Rv1 (D), C4-2 (E), and LNCaP (F) cell lines following treatment with varying concentrations of DSARTAC drugs. Immunoblotting analysis of AR and AR-V7 protein levels in the presence of carfilzomib, in CWR22Rv1 (G), C4-2 (H), and LNCaP (I) cell lines following treatment with varying concentrations of DSARTAC drugs. IB analysis of WCLs from C4-2 cells (J) and CWR22Rv1 cells (K) treated with CHX for the indicated times, with or without 6.3 μM DSARTC drug treatment.